<p>Prenetics Global Limited（纳斯达克代码：PRE - 获取免费报告）在周四的交易中上涨了 3.2%。该股票最高交易价为 16.97 美元，最后交易价为 16.49 美元。在交易中，约有 170,202 股成交，较 136,406 股的日均成交量增加了 25%。该股票此前收盘价为 15.98 美元。</p>
<p>获取 <strong>Prenetics Global</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>几位股票研究分析师对 PRE 股票发布了报告。华尔街 Zen 在 11 月 15 日的研究报告中将 Prenetics Global 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Prenetics Global 的 “卖出（d-）” 评级。最后，Cantor Fitzgerald 在 10 月 29 日的报告中将 Prenetics Global 的目标价格从 26.00 美元上调至 32.00 美元，并给予该股票 “增持” 评级。一位投资分析师对该股票给予了买入评级，而另一位则对该公司给予了卖出评级。根据 MarketBeat 的数据，Prenetics Global 目前的平均评级为 “持有”，共识目标价格为 32.00 美元。</p>
<p><strong>阅读我们关于 Prenetics Global 的最新报告</strong></p>
<h2>Prenetics Global 股票上涨 3.2%</h2>
<p>该公司的 50 日简单移动平均线为 14.19 美元，200 日简单移动平均线为 10.84 美元。该股票的市值为 2.7753 亿美元，市盈率为-8.12，贝塔值为 0.35。</p>
<p>Prenetics Global（纳斯达克代码：PRE - 获取免费报告）最近在 11 月 10 日发布了其财报。公司报告本季度每股收益为（0.41 美元），超出市场共识预期的（0.55 美元）0.14 美元。Prenetics Global 的股本回报率为-30.12%，净利润率为-60.70%。该公司本季度的收入为 2356 万美元，而市场共识预期为 2600 万美元。分析师平均预计 Prenetics Global Limited 在本年度的每股收益为-3.3。</p>
<h2>对 Prenetics Global 的对冲基金看法</h2>
<p>几位大型投资者最近调整了对该股票的持有。摩根大通在第三季度购买了 Prenetics Global 的新股份，金额约为 65,000 美元。Stevens Capital Partners 在第二季度收购了 Prenetics Global 的新股份，金额约为 137,000 美元。瑞银集团在第三季度将其在 Prenetics Global 的持股增加了 581.9%。瑞银集团目前拥有 46,561 股该公司的股票，价值 619,000 美元，此前在此期间又购买了 39,733 股。阿伯丁集团在第三季度收购了价值约 979,000 美元的 Prenetics Global 新股份。最后，野村控股在第一季度将其在 Prenetics Global 的持股增加了 3.3%。野村控股目前拥有 333,528 股该公司的股票，价值 1,307,000 美元，此前在此期间又购买了 10,576 股。25.01% 的股票由机构投资者持有。</p>
<h2>Prenetics Global 公司简介</h2>
<p>（获取免费报告）</p>
<p>Prenetics Global Limited 是一家以基因组学为驱动的健康科学公司，致力于革命性地改变预防、早期检测和治疗。它提供 CircleDNA，一个利用全外显子组测序提供全面消费者 DNA 测试的预防项目。该公司还通过其合资企业 Insighta，致力于开创多癌症早期检测技术。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Prenetics Global</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>保护您的投资组合免受冠状病毒影响的三只股票</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>三只股票引领迷因股复兴</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Prenetics Global 吗？</h2>
<p>在您考虑投资 Prenetics Global 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Prenetics Global 并不在名单上。</p>
<p>虽然 Prenetics Global 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Prenetics Global (NASDAQ:PRE) 的股价上涨了 3.2%，达到 16.49 美元，交易量增加了 25%。分析师的评级各不相同：华尔街禅将评级上调至 “买入”，Weiss Ratings 维持 “卖出” 评级，Cantor Fitzgerald 将目标价上调至 32.00 美元。Prenetics 报告了第三季度的收益，每股亏损 0.41 美元，超出预期。机构投资者增加了持股。该公司专注于基因组驱动的健康科学和早期癌症检测技术</p>

<p>Prenetics Global Limited (NASDAQ:PRE - Get Free Report) shares were up 3.2% during trading on Thursday . The stock traded as high as $16.97 and last traded at $16.49. Approximately 170,202 shares traded hands during trading, an increase of 25% from the average daily volume of 136,406 shares. The stock had previously closed at $15.98.</p>
<div class="lb-trans"><p>Prenetics Global Limited（纳斯达克代码：PRE - 获取免费报告）在周四的交易中上涨了 3.2%。该股票最高交易价为 16.97 美元，最后交易价为 16.49 美元。在交易中，约有 170,202 股成交，较 136,406 股的日均成交量增加了 25%。该股票此前收盘价为 15.98 美元。</p>
</div><p>Get <strong>Prenetics Global</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prenetics Global</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities research analysts have issued reports on PRE shares. Wall Street Zen upgraded shares of Prenetics Global from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 15th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Prenetics Global in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald upped their target price on Prenetics Global from $26.00 to $32.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prenetics Global currently has an average rating of &#34;Hold&#34; and a consensus price target of $32.00.</p>
<div class="lb-trans"><p>几位股票研究分析师对 PRE 股票发布了报告。华尔街 Zen 在 11 月 15 日的研究报告中将 Prenetics Global 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Prenetics Global 的 “卖出（d-）” 评级。最后，Cantor Fitzgerald 在 10 月 29 日的报告中将 Prenetics Global 的目标价格从 26.00 美元上调至 32.00 美元，并给予该股票 “增持” 评级。一位投资分析师对该股票给予了买入评级，而另一位则对该公司给予了卖出评级。根据 MarketBeat 的数据，Prenetics Global 目前的平均评级为 “持有”，共识目标价格为 32.00 美元。</p>
</div><p><strong>Read Our Latest Report on Prenetics Global</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Prenetics Global 的最新报告</strong></p>
</div><h2>Prenetics Global Stock Up 3.2%</h2>
<div class="lb-trans"><h2>Prenetics Global 股票上涨 3.2%</h2>
</div><p>The firm has a 50 day simple moving average of $14.19 and a 200-day simple moving average of $10.84. The stock has a market cap of $277.53 million, a P/E ratio of -8.12 and a beta of 0.35.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 14.19 美元，200 日简单移动平均线为 10.84 美元。该股票的市值为 2.7753 亿美元，市盈率为-8.12，贝塔值为 0.35。</p>
</div><p>Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%.The company had revenue of $23.56 million during the quarter, compared to the consensus estimate of $26.00 million. On average, equities analysts anticipate that Prenetics Global Limited will post -3.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>Prenetics Global（纳斯达克代码：PRE - 获取免费报告）最近在 11 月 10 日发布了其财报。公司报告本季度每股收益为（0.41 美元），超出市场共识预期的（0.55 美元）0.14 美元。Prenetics Global 的股本回报率为-30.12%，净利润率为-60.70%。该公司本季度的收入为 2356 万美元，而市场共识预期为 2600 万美元。分析师平均预计 Prenetics Global Limited 在本年度的每股收益为-3.3。</p>
</div><h2>Hedge Funds Weigh In On Prenetics Global</h2>
<div class="lb-trans"><h2>对 Prenetics Global 的对冲基金看法</h2>
</div><p>Several large investors have recently modified their holdings of the stock. JPMorgan Chase &amp; Co. bought a new stake in shares of Prenetics Global during the 3rd quarter worth about $65,000. Stevens Capital Partners acquired a new stake in Prenetics Global during the second quarter worth approximately $137,000. UBS Group AG boosted its holdings in shares of Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company's stock worth $619,000 after acquiring an additional 39,733 shares during the period. Aberdeen Group plc acquired a new position in shares of Prenetics Global in the third quarter valued at approximately $979,000. Finally, Nomura Holdings Inc. increased its stake in shares of Prenetics Global by 3.3% during the first quarter. Nomura Holdings Inc. now owns 333,528 shares of the company's stock worth $1,307,000 after purchasing an additional 10,576 shares during the period. 25.01% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几位大型投资者最近调整了对该股票的持有。摩根大通在第三季度购买了 Prenetics Global 的新股份，金额约为 65,000 美元。Stevens Capital Partners 在第二季度收购了 Prenetics Global 的新股份，金额约为 137,000 美元。瑞银集团在第三季度将其在 Prenetics Global 的持股增加了 581.9%。瑞银集团目前拥有 46,561 股该公司的股票，价值 619,000 美元，此前在此期间又购买了 39,733 股。阿伯丁集团在第三季度收购了价值约 979,000 美元的 Prenetics Global 新股份。最后，野村控股在第一季度将其在 Prenetics Global 的持股增加了 3.3%。野村控股目前拥有 333,528 股该公司的股票，价值 1,307,000 美元，此前在此期间又购买了 10,576 股。25.01% 的股票由机构投资者持有。</p>
</div><h2>Prenetics Global Company Profile</h2>
<div class="lb-trans"><h2>Prenetics Global 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.</p>
<div class="lb-trans"><p>Prenetics Global Limited 是一家以基因组学为驱动的健康科学公司，致力于革命性地改变预防、早期检测和治疗。它提供 CircleDNA，一个利用全外显子组测序提供全面消费者 DNA 测试的预防项目。该公司还通过其合资企业 Insighta，致力于开创多癌症早期检测技术。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Prenetics Global</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Prenetics Global</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>保护您的投资组合免受冠状病毒影响的三只股票</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>三只股票引领迷因股复兴</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prenetics Global Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Prenetics Global 吗？</h2>
</div><p>Before you consider Prenetics Global, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑投资 Prenetics Global 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Prenetics Global 并不在名单上。</p>
</div><p>While Prenetics Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prenetics Global 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Prenetics Global (NASDAQ:PRE) 股价上涨 3.2% - 事情经过